Eltrombopag Induced Liver Dysfunction During Treatment of Immunethrombocytopenic Purpura
Recruiting
N/A
Interventional Study
ITP - Immune Thrombocytopenia
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 100 (estimated)
- Sponsor
- Sohag University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
this study amis to assess the incidence and severity of liver dysfunction in ITP patients receiving eltrombopag.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria Adult patients (≥18 years) diagnosed with primary ITP. Receiving eltrombopag as part of their treatment. Baseline liver function tests (LFTs) within normal limits. Patients with diabetes Patients without diabetes Patients with fatty liver Patients without fatty liver
Exclusion Cr…
Contacts
Usama M Abdelaal, Professor
01065962094
CONTACT